Deprecated: Non-static method JSite::getMenu() should not be called statically, assuming $this from incompatible context in /eu.cbdna/public_html/templates/gk_shop_and_buy/lib/framework/helper.layout.php on line 148

Deprecated: Non-static method JApplication::getMenu() should not be called statically, assuming $this from incompatible context in /eu.cbdna/public_html/includes/application.php on line 536

918 Genetic multiorgan predisposition for neoplasm – analysis of mutations of gene CHEK2

The test covers 3 changes (1100delC, IVS2+1GA, I157T) within CHEK2 gene . Variants of this gene increase the risk of developing mainly breast cancer, colorectal cancer, prostate cancer, thyroid carcinoma and kidney carcinoma.

Mutations shortening protein (1100delC, IVS2+1GA) increase the risk of developing: breast cancer (ca. 2.4-fold), prostate cancer (ca. 2.3-fold or 5-fold in family cases), medullary thyroid cancer (ca. 5-fold). "Missense" type of mutation (I157T) increases ca. 1.5-fold the risk of developing breast cancer, 1.6-fold prostate cancer, and also kidney carcinoma (ca. 2-fold), colorectal cancer (ca. 2-fold), medullary thyroid cancer (ca. 2-fold).

This mutation also increases ca. 2-fold the risk of developing ovary cancer with low level of morphological malignancy and 2.5-fold ovary cancer with borderline malignancy. Patients with a mutation in gene CHEK2 and family occurrence of breast cancer are exposed to the risk of developing neoplasm at the level of 25%. Approximately 1/100 people is a carrier of such mutation in Poland. It is recommended to make a carriage test on variant CHEK2 simultaneously with mutations in BRCA1 and BRCA2.

Test material: full blood (EDTA), cheek swab

Transfer method: blood: 4-10°C (a set for blood tests); cheek swab: room temperature (a set for cheek swabs)

Testing method: Direct sequencing of respective gene’s fragments

Delivery date: up to 10 business days